About CEL-SCI

History

CEL-SCI’s story is one of vision, persistence, and survival in the face of overwhelming odds. Despite downturns in the biotech sector, lack of funding, and a lengthy clinical trial process associated with the development of its cancer therapy, CEL-SCI is finally at the end game! Our lead cancer product, Multikine®, has performed well in Phase II trials, and is now approved for a global Phase III trial. More...

Mission and Values

Our mission is to improve the treatment of cancer and other diseases by unleashing and empowering the immune system; the body’s natural and most powerful defense system.

We strive to create real value for our stakeholders by developing unique best-in-class non-toxic therapies that address unmet medical needs. More...

Business Strategy

CEL-SCI’s vision is to change the way cancer is treated.  We develop novel immune-based therapies that harness the body’s own immune defense system to fight disease. These therapies are effective and non-toxic to the body’s normal cells and organ systems, unlike traditional cancer therapies such as chemotherapy, radiation and surgery, which are most often highly toxic or damaging. More...

Corporate Overview

CEL-SCI Corporation (AMEX: CVM), a biotechnology company, was formed in 1983.

CEL-SCI is involved in the research and development of immunotherapy products for the treatment of cancer and infectious diseases.

The Company’s core capabilities include: drug discovery, research, development and manufacturing of complex biological substances. More...

Corporate Headquarters

CEL-SCI Corporation
8229 Boone Boulevard, Suite 802
Vienna, VA 22182  USA
Telephone (703)  506-9460
Facsimile (703) 506-9471 More...

Management Team